Antitumor agents including mitomycin C (MMC) and methotrexate (MTX) were coupled to monoclonal antibodies against murine bladder tumor cell line MBT-2 for the purpose of enhancing their drug activity. MMC was conjugated with antibody through two carriers, periodate-oxidized dextran and dithiopyridylated serum albumin, and MTX was conjugated with antibody either directly or through dithiopyridylated serum albumin or poly-L-lysine via an amide bond. These conjugates were assayed for growth inhibitory effect on MBT-2 bladder tumor cells, MCA clone 15 embryo cells and P388 leukemic cells. The cytotoxicity tests demonstrated that drug-antibody immune conjugates were 10 to 100 times more cytotoxic against antibody-reactive MBT-2 cells than nonimmune drug conjugates and showed a similar level of cytotoxicity against antibodynonreactive cells to that of the nonimmune conjugates. This selective cytotoxicity was also confirmed by competitive inhibition of unconjugated antibody, showing a dependency on antibody binding to the target cell surface antigens. The targeting effect was further assessed by evaluating the suppression of tumor growth subsequent to in vitro treatment of MBT-2 cells with immune conjugates. Half of the mice receiving cells treated with immune conjugates survived more than 40 d after inoculation, while none or one of 7 mice receiving cells treated with unconjugated drug, antibody alone or nonimmune conjugates survived at 40 d after inoculation.
The idea of targeting cytotoxic agents was proposed by Ehrlich at the beginning of the century,1) but such a goal has become feasible only with the recent advent of monoclonal antibody production.2) Monoclonal antibodies, because of their purity and specificity, and the ability to obtain them in large quantities, represent very attractive carriers for tumor therapeutic agents.3) Many cytotoxic agents coupled with monoclonal antibodies have been proposed and investigated for cancer chemotherapy with various degrees of success.4) Among them, immunotoxins prepared by coupling biological toxins to antibodies have received much attention because of their enormous cytotoxic potential.5) Such an approach would, however, appear to require absolute tumor specificity of monoclonal antibodies in order not to damage normal tissues, and it is probably unrealistic to expect to obtain such truly tumor-specific antibodies. An alternative is to couple conventional chemotherapeutic drugs which have acceptable side effects. Such antibody-targeted drugs would be expected to provide either improved therapeutic effects or reduced side effects. Several researchers reported successful conjugates prepared by direct coupling of drugs to antibodies,6) but this type of conjugate has the drawback that there are only a small number of functional groups available per antibody molecule which can be used for chemical coupling without significant loss of antibody binding activity. Then a carrier molecule was used to which the drug was attached and which in turn was linked to the antibody in order to obtain a higher molar ratio of drug to antibody. Dextran,4a,7) serum albumin4b, 8) and synthetic polypeptides such as poly-L-glutamic acid9) were used for this purpose.
We have developed two monoclonal antibodies to the cell surface antigens of chemicallyinduced transitional cell carcinomas of mouse urinary bladder.1°1 The tumor cell line was initiated from primary FANFT (N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide)-induced murine bladder tumors arising in C3H/He mice and established as a stable cell line MBT-2, which is useful as an in vitro model for bladder cancer. In the present study we have conjugated these monoclonal antibodies with mitomycin C (MMC) and methotrexate (MTX), which are widely used in cancer chemotherapy, but the utility of which is limited by several side effects including severe bone marrow depression and gastrointestinal damage. Dextran, human serum albumin (HSA) and poly-L-lysine (PLL) were chosen as carrier molecules because of their good biological stability in aqueous solutions, and MMC or MTX molecules were coupled to monoclonal antibodies through the carriers. This paper describes the selective cytotoxicity of these drug-antibody conjugates against murine bladder tumor cells.
Experimental Target  Cells  Three  established  murine  cell  lines  (MBT-2 (Table III) . In a test against MBT-2 cells, MMC-HSA-7-4B6-2) conjugate showed more than 10 times higher cytotoxicity than nonimmune conjugate MMC-HSA-DTP, although the former conjugate had the same inhibitory effect as the latter conjugate on MCA clone 15 cell growth. Moreover, the cytotoxic effect of the immune conjugate was 10 to 15 times that of free MMC and the covalent coupling of specific antibody to MMC was found to considerably increase its cytotoxicity. This increased cytotoxicity of MMC-HSA-antibody conjugate was diminished in the presence of free antibody , as was that of MMC-PADantibody conjugate described above, and these results suggest that the cytotoxicity of the antibody conjugates was dependent upon antibody binding to the target cells .
MTX-Antibody Conjugates MTX-antibody conjugates were also tested for in vitro cytotoxicity against MBT-2 bladder tumor cells . Nonimmune conjugates MTX-HSA-DTP and MTX-PLL-DTP were used as controls. The target cells were exposed to these drug solutions at 37C for 100 min, washed and cultivated in fresh growth medium for several days. Immune conjugates including MTX-7-4B6-2) showed about 10 times higher cytotoxicity than free MTX, while nonimmune conjugates were 4 to 10 times less toxic to MBT-2 cells (Table IV) . Since unconjugated antibody 7-4B6-2 was not toxic at concentrations which were equivalent to those in the immune conjugates, the immune conjugates showed the increased cytotoxicity through antibody binding to the target cells. These results mean that 
Discussion
HellstrOm et al.13) established two hybridomas secreting antibodies to antigens that are more strongly expressed in mouse transitional-cell bladder carcinomas than in other mouse tumors or normal tissues. We have also cloned two hybridomas, 1-3C6-9 and 7-4B6-2, secreting antibodies which preferably bind to a stable cell line of mouse bladder tumor. Although the monoclonal antibodies were not strictly specific for bladder carcinoma, since binding to cells from some control tissues or to embryonal cells was detected, they were employed to assess the therapeutic applicability of drug coupling with monoclonal antibody directed against tumor cell surface antigens.
Several kinds of drug-ntibody conjugates were prepared with or without using dextran, albumin and polylysine as carriers in the present study. In the direct coupling of MTX and IgM antibody 7-4B6-2 without carriers, the extent of substitution was 31 mol of drug per mol 
